CG On­col­o­gy touts in­ter­im Phase 3 blad­der can­cer da­ta, gears up to com­pete with Im­mu­ni­ty­Bio

An ex­per­i­men­tal on­colyt­ic virus ther­a­py de­vel­oped by CG On­col­o­gy helped clear tu­mors in 75% of blad­der can­cer pa­tients in a Phase 3 study.

The ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER